Article

UK’s NICE panel issues positive appraisal for Iluvien

The Appraisal Committee of the United Kingdom's National Institute for Health and Care Excellence (NICE) has issued a positive Appraisal Consultation Document (ACD) for the 190 µm fluocinolone acetonide intravitreal implant in applicator (Iluvien, Alimera Sciences) for the treatment of pseudophakic patients with chronic diabetic macular edema (DME) and who are unresponsive to existing therapies.

Alpharetta, GA-The Appraisal Committee of the United Kingdom's National Institute for Health and Care Excellence (NICE) has issued a positive Appraisal Consultation Document (ACD) for the 190 µm fluocinolone acetonide intravitreal implant in applicator (Iluvien, Alimera Sciences) for the treatment of pseudophakic patients with chronic diabetic macular edema (DME) and who are unresponsive to existing therapies.

The ACD recommended a change to the published guidance issued by NICE in January 2013, and took into consideration a simple patient access scheme (PAS) submitted by Alimera for rapid review.

The Appraisal Committee decision reconfirmed the product’s clinical effectiveness in the treatment of vision impairment associated with chronic DME. In the ACD, the committee emphasized, "that the technology had been shown to meet a clinical need in people whose disease is unresponsive to available therapies."

Additionally, the committee noted that, based on the PAS, the cost-effectiveness threshold has been met for a subgroup of chronic DME patients who are pseudophakic or have already undergone cataract replacement surgery.

"I am delighted that the Appraisal Committee has reconsidered the NICE guidance on [the implant]," said Winfried Amoaku, associate professor and consultant ophthalmologist with Nottingham University Hospitals NHS Trust. "Chronic DME patients who are pseudophakic are now one step closer to receiving this crucial sight-saving treatment from the National Health Service.”

Dan Myers, Alimera's president and chief executive officer, was also pleased with the Appraisal Committee's recommendation. He added that Alimera is optimistic that the ACD will lead to a change in the final published guidance.

“We believe that [the implant] is also effective in other groups of DME patients,” Myers said. “We plan to continue to work with NICE to broaden access to Iluvien to include all chronic DME patients who could benefit from the treatment.”

For more articles in this issue of Ophthalmology Times eReport, click here.

 

 

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.